Show simple item record

dc.contributor.authorHassapis, K. A.en
dc.contributor.authorKostrikis, Leontios G.en
dc.creatorHassapis, K. A.en
dc.creatorKostrikis, Leontios G.en
dc.date.accessioned2019-11-04T12:50:41Z
dc.date.available2019-11-04T12:50:41Z
dc.date.issued2013
dc.identifier.issn1570-162X
dc.identifier.urihttp://gnosis.library.ucy.ac.cy/handle/7/53123
dc.description.abstractAntigen-presenting viral vectors have been extensively used as vehicles for the presentation of antigens to the immune system in numerous vaccine strategies. Particularly in HIV vaccine development efforts, two main viral vectors have been used as antigen carriers: (a) live attenuated vectors and (b) virus-like particles (VLPs)en
dc.description.abstractthe former, although highly effective in animal studies, cannot be clinically tested in humans due to safety concerns and the latter have failed to induce broadly neutralizing anti-HIV antibodies. For more than two decades, Inoviruses (non-lytic bacterial phages) have also been utilized as antigen carriers in several vaccine studies. Inoviral vectors are important antigen-carriers in vaccine development due to their ability to present an antigen on their outer architecture in many copies and to their natural high immunogenicity. Numerous fundamental studies have been conducted, which have established the unique properties of antigen-displayed inoviral vectors in HIV vaccine efforts. The recent isolation of new, potent anti-HIV broadly neutralizing monoclonal antibodies provides a new momentum in this emerging technology. © 2013 Bentham Science Publishers.en
dc.sourceCurrent HIV Researchen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84900480020&doi=10.2174%2f1570162X12666140209135651&partnerID=40&md5=e13cbc930a1132b4bb4ecde9ccd34646
dc.subjectarticleen
dc.subjecthumanen
dc.subjectHumansen
dc.subjectgene producten
dc.subjectHIV Infectionsen
dc.subjectnonhumanen
dc.subjectimmune responseen
dc.subjectimmunologyen
dc.subjectgeneticsen
dc.subjectHuman immunodeficiency virus antibodyen
dc.subjectgene mutationen
dc.subjectHuman immunodeficiency virus 1en
dc.subjectHIV-1en
dc.subjectGag proteinen
dc.subjectDNA sequenceen
dc.subjectvaccinationen
dc.subjectcrystal structureen
dc.subjectGenetic Vectorsen
dc.subjectvirus vectoren
dc.subjectHuman immunodeficiency virus vaccineen
dc.subjectbacteriophageen
dc.subjectgene vectoren
dc.subjectAIDS Vaccinesen
dc.subjectAntigen-displayen
dc.subjectBacteriophagesen
dc.subjectepitope mappingen
dc.subjectglycoprotein gp 120en
dc.subjectglycoprotein gp 41en
dc.subjectHIV Antigensen
dc.subjectHIV neutralizing antibodiesen
dc.subjectHIV vaccineen
dc.subjectHuman immunodeficiency virus antigenen
dc.subjectimmunogenicityen
dc.subjectInoviridaeen
dc.subjectInovirus-displayen
dc.subjectpeptide libraryen
dc.subjectPhage-displayen
dc.subjectscanning transmission electron microscopyen
dc.subjectViral vectorsen
dc.subjectvirus like particle vaccineen
dc.titleHIV-1 vaccine strategies utilizing viral vectors including antigen-displayed inoviral vectorsen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2174/1570162X12666140209135651
dc.description.volume11
dc.description.startingpage610
dc.description.endingpage622
dc.author.facultyΣχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences
dc.author.departmentΤμήμα Βιολογικών Επιστημών / Department of Biological Sciences
dc.type.uhtypeArticleen
dc.description.notes<p>Cited By :1</p>en
dc.source.abbreviationCurr.HIV Res.en
dc.contributor.orcidKostrikis, Leontios G. [0000-0002-5340-7109]
dc.gnosis.orcid0000-0002-5340-7109


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record